Self-assembling micelle-nanocarrier therapeutic device, with encapsulated rapamycin used in targeted immunosuppression during solid organ transplantation. Designed with environment-sensitive construct with targeting moiety. Micelles are conjugated with imaging-agents to track uptake and monitor biodistribution. Delivery method allows for lower dosing strategies vs free-drug strategies, with effects seen in multiple animal models.
Primary Application Area: Medical Devices
Technology Development Status: Prototype
FIGURES OF MERIT
Value Proposition: Organ transplantation has become an accepted modality for the treatment of end-stage organ failure. The field of transplant medicine has made tremendous strides with more potent immunosuppressive medications reducing acute rejection episodes. However, chronic rejection remains a leading cause of graft loss in the long term. 15-20% of kidney transplants will be rejected in 3-5 years. Up to 50% of heart and lung organ transplants will be rejected. Current immunosuppressive therapies used in organ transplantation globally depress the immune system and consequently lead to detrimental systemic side effects. By offering targeted immunotherapies with a novel targeting and tracking moieties, these systemic and often fatal side effects can be alleviated.
Organization Type: Early-stage Startup (Seed)
Showcase Booth #: 301
GOVT/EXTERNAL FUNDING SOURCES
Vetted Programs/Awards: Bioprocesses International “Emerging Company Award,” 2014; Co-Founder Satish Nadig named Charleston’s 40 under 40 for ToleRaM Nanotech, 2014
External Funding to Date: SCRA University Start-up Assistance Program Award, 2015 ($25K)